Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer

[1]  Y. Muraoka,et al.  Prognostic impact of the histological lepidic component in pStage IA adenocarcinoma. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  D. Gossot.  Lobar or sublobar resection for early-stage lung cancer: at the crossroads. , 2021, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[3]  X. Yi,et al.  Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity. , 2021, American journal of respiratory and critical care medicine.

[4]  T. Cascone,et al.  What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Ho Yun Lee,et al.  Are radiomics features universally applicable to different organs? , 2021, Cancer Imaging.

[6]  A. Wozniak,et al.  Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer , 2021, Clinical lung cancer.

[7]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[8]  Jing Wang,et al.  Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities , 2020, Journal of thoracic disease.

[9]  Jules Lin.  Commentary: Through the looking glass: Is the consolidation/tumor ratio more important than size for clinical T1N0 lung cancer with a dominant ground-glass opacity? , 2020, The Journal of thoracic and cardiovascular surgery.

[10]  H. Dienemann,et al.  Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2 cm, stage IA (7th edition of TNM staging system). , 2019, Lung cancer.

[11]  M. Tsuboi,et al.  Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma. , 2019, The Annals of thoracic surgery.

[12]  Z. Szallasi,et al.  Neoantigen-directed immune escape in lung cancer evolution , 2019, Nature.

[13]  Takuo Hayashi,et al.  Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  H. Hsu,et al.  The role of the ground-glass opacity ratio in resected lung adenocarcinoma , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  I. Sohn,et al.  Comprehensive Computed Tomography Radiomics Analysis of Lung Adenocarcinoma for Prognostication. , 2018, The oncologist.

[16]  Kenji Suzuki,et al.  Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer. , 2017, The Annals of thoracic surgery.

[17]  A. Nicholson,et al.  The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part‐Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  A. Neugut,et al.  Limited Resection Versus Lobectomy for Older Patients With Early-Stage Lung Cancer: Impact of Histology. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Ho Yun Lee,et al.  Clinical Impact of Minimal Micropapillary Pattern in Invasive Lung Adenocarcinoma: Prognostic Significance and Survival Outcomes , 2015, The American journal of surgical pathology.

[21]  W. Travis.  The 2015 WHO classification of lung tumors , 2014, Der Pathologe.

[22]  David R. Jones,et al.  The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. , 2014, Seminars in thoracic and cardiovascular surgery.

[23]  Ho Yun Lee,et al.  Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. , 2014, The Journal of thoracic and cardiovascular surgery.

[24]  Masahiko Kusumoto,et al.  Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. , 2013, The Journal of thoracic and cardiovascular surgery.

[25]  S. Toyabe,et al.  Predictive Risk Factors for Mediastinal Lymph Node Metastasis in Clinical Stage IA Non–Small-Cell Lung Cancer Patients , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  V. Rusch,et al.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. , 2011, The Journal of thoracic and cardiovascular surgery.

[27]  Wendy J. Post,et al.  Volumetric measurement of pulmonary nodules at low-dose chest CT: effect of reconstruction setting on measurement variability , 2009, European Radiology.

[28]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  D. Xu,et al.  Nodule management protocol of the NELSON randomised lung cancer screening trial. , 2006, Lung cancer.

[30]  Albert Westergren,et al.  Statistical methods for assessing agreement for ordinal data. , 2005, Scandinavian journal of caring sciences.

[31]  B. Johnson,et al.  Second lung cancers in patients after treatment for an initial lung cancer. , 1998, Journal of the National Cancer Institute.

[32]  David R. Jones,et al.  Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)‐Positive T1 Lung Adenocarcinoma: A Propensity Score–Matched Analysis , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  M. Roizen.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[35]  Yang Xue-ning.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[36]  D. Lynch,et al.  The National Lung Screening Trial: overview and study design. , 2011, Radiology.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..